Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2017-04-18 Major Shareholding Noti…
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2017
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding for 'Bure Equity AB (publ)' in relation to 'Xvivo Perfusion Aktiebolag'. Key phrases include 'Reason for major shareholding notification New share issue', and tables showing 'Before the transaction' and 'After the transaction' share quantities and percentages. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2017-04-18 English
First XPS™ sold to Australia and to the Netherlands
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press Release" dated April 12, 2017. It announces specific business developments: the first sales of the XPS™ system to Australia and the Netherlands, referencing prior announcements (Report on Operations 2016) and discussing pricing strategy and future potential. This content is characteristic of an announcement regarding business operations and sales updates, rather than a comprehensive financial report (10-K, IR), a formal management discussion (MDA), or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV). Since it is a general business update released via press release, and it doesn't fit the specific categories like ER (Earnings Release, which focuses on financial metrics), it is best classified as a general Regulatory Filing (RNS) or potentially a type of Investor Information, but RNS serves as the best general regulatory announcement fallback for press releases that aren't explicitly earnings or capital structure focused. Given the nature of the announcement (new market entry/sales update), RNS is the most appropriate general category for non-standard, time-sensitive corporate news releases.
2017-04-12 English
Australien och Nederländerna nya länder med XPS™
Regulatory Filings Classification · 95% confidence The document is titled "Pressmeddelande" (Press Release) and is dated April 12, 2017. It announces the expansion of the XPS™ system into Australia and the Netherlands, referencing a contract mentioned in the 2016 year-end report communication. The content focuses on a specific business development (new country sales/installations) and includes quotes from the CEO. Crucially, the final paragraph states: "Denna information är sådan information som Xvivo Perfusion AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Xvivo Perfusion AB (publ) is obliged to disclose according to the EU Market Abuse Regulation). This structure strongly indicates a mandatory regulatory disclosure of material, non-public information, which typically falls under general regulatory announcements or specific transaction/event disclosures. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific insider trade (DIRS), the most appropriate general category for a mandatory, time-sensitive regulatory announcement not covered elsewhere is Regulatory Filings (RNS). It is not an announcement *about* a report (RPA), but the report/disclosure itself.
2017-04-12 Swedish
KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I XVIVO PERFUSION AKTIEBOLAG (PUBL)
Share Issue/Capital Change Classification · 99% confidence The document is titled "KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I XVIVO PERFUSION AKTIEBOLAG (PUBL)" (Communication from the Extraordinary General Meeting) and details decisions made regarding a directed new share issue (Nyemission) approved by the shareholders. This relates to capital structure changes and fundraising activities. The key event is the approval of a new share issue directed towards institutional investors, which is a financing activity. This aligns best with the 'Capital/Financing Update' category (CAP). Although it relates to a general meeting, the core subject is the capital change, not the voting results (DVA) or general AGM materials (AGM-R). Since it is a formal announcement detailing the terms of a capital raise, CAP is the most specific fit.
2017-04-10 Swedish
SUMMARY FROM EXTRAORDINARY GENERAL MEETING OF XVIVO PERFUSION AKTIEBOLAG (PUBL)
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated April 10, 2017, summarizing the resolutions passed at an Extraordinary General Meeting (EGM). The key resolution approved was a new issue of shares (Private Placement) directed to institutional investors, which constitutes a change in the company's capital structure and share count. This action directly relates to fundraising or capital structure changes. While the EGM context might suggest AGM-R or DVA, the core subject is the approval of a share issue. The definition for Capital/Financing Update (CAP) covers 'Updates on company fundraising, financing activities, or capital structure changes.' Since this is the announcement of the outcome of a vote approving a share issue, CAP is the most specific fit over a general regulatory filing (RNS) or a voting result declaration (DVA), as the primary news is the capital change itself. The document length is moderate (5077 chars), suggesting it is the primary announcement, not just a notification of publication (RPA).
2017-04-10 English
Annual Report 2016
Annual Report Classification · 100% confidence The document is titled 'ÅRSREDOVISNING 2016' (Annual Report 2016) for XVIVO Perfusion AB. It contains a comprehensive overview of the company's 2016 performance, including a CEO statement, historical background, market description, financial statements (Räkningar - Koncernen/Moderbolaget), notes, and an audit report (Revisionsberättelse). This is clearly a full annual report, not an announcement or a summary. FY 2016
2017-04-04 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.